Meny

Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

Författare:
  • Donal Brennan
  • Sara Ek
  • Emma Doyle
  • Thomas Drew
  • Michael Foley
  • Grainne Flannelly
  • Darren P O´Conner
  • William M Gallagher
  • Sami Kilpinen
  • Olli-Pekka Kallioniemi
  • Karin Jirström
  • Colm O'Herlihy
  • Carl Borrebaeck
Publiceringsår: 2009
Språk: Engelska
Sidor: 1510-1517
Publikation/Tidskrift/Serie: European Journal of Cancer
Volym: 45
Nummer: 8
Dokumenttyp: Artikel i tidskrift
Förlag: Elsevier

Sammanfattning

Abstract

Background:

Current prognostic molecular markers for epithelial ovarian cancer (EOC) are

insufficient. The aim of the current study was to investigate the role of Sox11 in EOC

Methods:

Using an in silico transcriptomic screen Sox11 was identified as a potential EOC

biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC)

in 76 EOC cases, which were analyzed using automated algorithms to develop a

quantitative scoring model.

Results:

Sox11 mRNA expression was up-regulated in EOC compared to normal tissues.

Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in

40% of tumours, who had an improved recurrence free survival (RFS) (p= 0.002).

Multivariate analysis confirmed Sox11 was an independent predictor of improved RFS

after controlling for stage and grade.

Conclusions:

These data suggest that Sox11 is a new prognostic marker in EOC. Loss of SOX 11 is

associated with a decreased RFS and a more aggressive phenotype.

Nyckelord

  • Immunology in the medical area

Övriga

Published
  • CREATE Health
  • ISSN: 1879-0852

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu.se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen